Advancing Early Cardiovascular Drug Discovery

On the 10th October Cello Health Insight, in association with PMGroup, will look at the value of three areas of patient research that provide that ‘must have’ understanding: mapping the patient pathway, patient motivation and the dialogue between patient and HCP.

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder affecting some 40,000 individuals in Europe at any time, causing 10,000 deaths each year. As with other age-related neurodegenerative diseases, the drug development field is littered with inconclusive or negative trials. Modifying Immune Response and Outcomes in ALS (MIROCALS) is an international European Union H2020-funded trial of low-dose interleukin-2 in motor neuron disease (MND)/ALS. It aims to break this impasse in the development of disease-modifying agents through novel trial design, incident (early post-diagnosis) recruitment, integration of biomarkers/transcriptomics and cohort stratification. Join this webinar to hear about an overview of the study in addition to a discussion of the challenges both anticipated and unanticipated in recruiting participants recently diagnosed with a rare, rapidly disabling and ultimately life-limiting condition.

Vibrational Circular Dichroism (VCD) is used to determine the absolute configuration of compounds in solution. As a result, it doesn’t require crystalline substances.

Many pharma companies are seeking new ways of making drug development more efficient and cost-effective through innovation, new technologies and process evolution. This has led to an increase in the outsourcing of development activities to contract research partners who focus solely on disciplines such as discovery chemistry, clinical testing, and formulation development and manufacturing.